Instil Bio
Price & Volume
Stats
See more52W Range | $9.85-$92 |
Market Cap | $168.1M |
Shares Short | 812,235 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $138,000 |
Diluted EPS | -$11.97 |
News
See moreYahoo Finance • 11 days ago
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Yahoo Finance • last month
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Yahoo Finance • last month
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Yahoo Finance • 2 months ago
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
About
CEO | Mr. Bronson Crouch |
CFO | Dr. Sandeep Laumas M.D. |
Address | 3963 Maple Avenue, Dallas, TX, United States, 75219 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 14 |
